

116TH CONGRESS  
1ST SESSION

# H. R. 4244

To provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, and for other purposes.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 9, 2019

Mr. KELLY of Pennsylvania introduced the following bill; which was referred to the Committee on Energy and Commerce

---

## A BILL

To provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act, and for other purposes.

1       *Be it enacted by the Senate and House of Representa-*  
2       *tives of the United States of America in Congress assembled,*

3       **SECTION 1. SHORT TITLE.**

4       This Act may be cited as the “Market Access for Ge-  
5       neric Insulin Competition” or the “MAGIC Act”.

1 **SEC. 2. PROVIDING FOR A PATHWAY FOR APPROVAL OF**  
2 **CHEMICALLY SYNTHESIZED INSULIN UNDER**  
3 **AN ABBREVIATED NEW DRUG APPLICATION.**

4 (a) IN GENERAL.—Section 7002(e)(2) of the Patient  
5 Protection and Affordable Care Act (42 U.S.C. 262 note)  
6 is amended—

7 (1) in subparagraph (B), by redesignating  
8 clauses (i) and (ii) as subclauses (I) and (II), respec-  
9 tively, and moving the margins of such subclauses  
10 (as so redesignated) two ems to the right;

11 (2) in subparagraph (A), by striking “such bio-  
12 logical product” and inserting “(i) such biological  
13 product”;

14 (3) by redesignating subparagraph (B) as  
15 clause (ii) and moving the margin of such clause (as  
16 so redesignated) two ems to the right;

17 (4) in clause (ii) (as so redesignated), by strik-  
18 ing the period at the end and inserting “; or”; and

19 (5) by adding at the end the following:

20 “(B) notwithstanding paragraphs (3) and  
21 (4), the application is submitted under sub-  
22 section (j) of such section for chemically syn-  
23 thesized insulin or any analogue of chemically  
24 synthesized insulin for which the listed drug is  
25 a biological product that is, pursuant to para-

1 graph (4), deemed to be licensed under section  
2 351 of the Public Health Service Act.”.

3 (b) EFFECTIVE DATE.—The amendments made by  
4 this section shall apply with respect to applications sub-  
5 mitted on or after January 1, 2020.

○